This multicentre, randomised controlled trial will enrol 1000 patients presenting with septic shock to the emergency department (ED) of participating hospitals in Australia and New Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids and early vasopressor regimen or a larger initial IV fluid volume with later introduction of vasopressors if required. Clinical care including the type of resuscitation fluid and vasopressor agent, will otherwise be in accordance with accepted standard care and according to clinician discretion. The study intervention will be delivered for at least 6 hours and up to 24 hours post-randomisation. Participants will be followed for up to 12 months and outcomes analysed on an intention-to-treat basis.
The ARISE FLUIDS study is a multicentre, randomised, parallel group clinical trial of a restricted fluids and early vasopressor strategy compared to a larger initial IV fluid volume and later vasopressors for the haemodynamic resuscitation of patients with septic shock presenting to the ED. It will be conducted in hospitals in Australia and New Zealand with 1000 patients recruited over a 3-year period. Each patient meeting all of the inclusion and none of the exclusion criteria will be randomised to receive haemodynamic resuscitation using either a restricted fluid and early vasopressor regimen (vasopressors arm) or a larger initial fluid resuscitation volume (fluids arm) followed by later introduction of vasopressors (if required). The intervention will be commenced in the ED and delivered for at least 6 hours, and up to 24 hours post-randomisation if admitted to the ICU or other critical care area where the study protocol can be faithfully delivered. Treatment will revert to usual care as determined by the treating clinician when the patient is transferred to a non-critical care ward. All enrolled participants will be followed up and assessed for the defined study outcomes. Participants will be identified using a systematic approach to screening and assessment of patients with possible sepsis presenting to the ED in accordance with standard clinical practice.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,000
Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
Bankstown Hospital
Bankstown, New South Wales, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Nepean Hosital
Kingswood, New South Wales, Australia
John Hunter Hospital
New Lambton Heights, New South Wales, Australia
Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia
Days alive and out of hospital
the number of days alive and out of hospital at 90 days post randomization
Time frame: From randomisation until 90 days post- randomization
Mortality
All-cause mortality
Time frame: From randomisation until 90 days post- randomization
Time from randomization until death
Time from randomization until death
Time frame: From randomisation until 90 days post- randomization
Days alive and at home
Days alive and at home at 90 days post-randomisation
Time frame: From randomisation until 90 days post- randomization
Ventilator-free days to day 28
Number of days not on invasive mechanical ventilation
Time frame: From randomisation until 28 days post- randomization
Vasopressor-free days to day 28
Number of days not on vasopressors
Time frame: From randomisation until 28 days post- randomization
Renal replacement therapy-free days to day 28
Number of days not on renal replacement therapy
Time frame: From randomisation until 28 days post- randomization
Death or disability at 6 months
Death or disability as measured by the World Health Organization Disability Assessment Schedule (WHODAS)
Time frame: at 6 months post randomization
Death or disability at 12 months
Death or disability as measured by the World Health Organization Disability Assessment Schedule (WHODAS)
Time frame: at 12 months post randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Royal North Shore Hosptial
Sydney, New South Wales, Australia
Ryde Hospital
Sydney, New South Wales, Australia
Tamworth Hospital
Tamworth, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Darwin & Palmerston Hospital
Darwin, Northern Territory, Australia
...and 40 more locations